Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer???a pilot study

Methoxy Poly(ethylene glycol)-Poly(lactide) Nanoparticles Encapsulating Quercetin Act as an Effective Anticancer Agent by Inducing Apoptosis in Breast Cancer

“…Earlier reports suggested increased drug concentration in peritumoral region and lymph nodes after peritumoral injection of drug adsorbed onto activated carbon particles for loco-regional chemotherapy for breast cancer [17]. This approach was considered effective for tumors sites which are easily accessible.…”

Targeting colloidal particulates to thoracic lymph nodes

“…Required amounts of water, PVP and sodium chloride were added so each millilitres of the final suspension contained 50, 20 and 9 mg of charcoal, PVP and sodium chloride, respectively. For comparison, we also obtained samples of activated charcoal (CH40) from Dr. A. Hagiwara, which were used in various clinical studies [19,20]. These samples contained the same composition as those prepared by our group.…”

“…A consistent finding in these studies is that the colloidal particles administered interstitially are mainly taken up by the regional lymphatic system and accumulate to varying degrees in the lymph nodes. This unique selective biodistribution led to the development of lymphatic targeting drug delivery systems utilizing colloidal materials as drug carriers, such as liposomes [8][9][10], activated carbon particles [11,12], emulsions [13,14], lipids [15] and various polymeric particulates [16,17]. However, lymphatic distribution of particles of different materials and sizes following intrapleural administration has not been investigated.…”

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

“…Aclarubicin adsorbed onto activated carbon particles has been tested after subcutaneous injection in mice, against a murine model (P288 leukemia cells) of lymph node metastases [52]. The same system has also been used as a locoregional chemotherapy adjuvant for breast cancer in patients after intratumoral and peritumoral injections [53]. In both cases, this carrier system distributed selectively high levels of free aclarubicin to the regional lymphatic system and low levels to the rest of the body.…”